The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Mechanism of biological synergy between cellular Src and epidermal growth factor receptor
Open accessAbstract
Overexpression of both cellular Src (c-Src) and the epidermal growth factor receptor (EGFR) occurs in many of the same human tumors, suggesting that they may functionally interact and contribute to the progression of cancer. Indeed, in murine fibroblasts, overexpression of c-Src has been shown to potentiate the mitogenic and tumorigenic capacity of the overexpressed EGFR. Potentiation correlated with the ability of c-Src to physically associate with the activated EGFR and the appearance of two unique in vivo phosphorylations on the receptor (Tyr-845 and Tyr-1101). Using stable cell lines of C3H10T½ murine fibroblasts that contain kinase-deficient (K−) c-Src and overexpressed wild-type EGFR, we show that the kinase activity of c-Src is required for both the biological synergy with the receptor and the phosphorylations on the receptor, but not for the association of c-Src with the receptor. In transient transfection assays, not only epidermal growth factor but also serum- and lysophosphatidic acid-induced DNA synthesis was ablated in a dominant-negative fashion by a Y845F mutant of the EGFR, indicating that c-Src-induced phosphorylation of Y845 is critical for the mitogenic response to both the EGFR and a G protein-coupled receptor (lysophosphatidic acid receptor). Unexpectedly, the Y845F mutant EGFR was found to retain its full kinase activity and its ability to activate the adapter protein SHC and extracellular signal-regulated kinase ERK2 in response to EGF, demonstrating that the mitogenic pathway involving phosphorylation of Y845 is independent of ERK2-activation. The application of these findings to the development of novel therapeutics for human cancers that overexpress c-Src and EGFR is discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
The Protein Kinase Family: Conserved Features and Deduced Phylogeny of the Catalytic Domains
Hanks, S. K., Quinn, A. M., & Hunter, T. (1988) · Science · doi:10.1126/science.3291115 · Cited by 5,039
Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors
Daub, H., Ulrich Weiss, F., Wallasch, C., & Ullrich, A. (1996) · Nature · doi:10.1038/379557a0 · Cited by 1,476
Ellis, L., Clauser, E., Morgan, D. O., Edery, M., Roth, R. A., & Rutter, W. J. (1986) · Cell · doi:10.1016/0092-8674(86)90786-5 · Cited by 1,070
A role for Pyk2 and Src in linking G-protein-coupled receptors with MAP kinase activation
Dikic, I., Tokiwa, G., Lev, S., Courtneidge, S. A., & Schlessinger, J. (1996) · Nature · doi:10.1038/383547a0 · Cited by 954
Hubbard, S. R. (1997) · The EMBO Journal · doi:10.1093/emboj/16.18.5572 · Cited by 953
Biscardi, J. S., Maa, M.-C., Tice, D. A., Cox, M. E., Leu, T.-H., & Parsons, S. J. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.12.8335 · Cited by 649
Self-citationDi Fiore, P. P., Pierce, J. H., Fleming, T. P., Hazan, R., Ullrich, A., King, C. R., Schlessinger, J., & Aaronson, S. A. (1987) · Cell · doi:10.1016/0092-8674(87)90592-7 · Cited by 640
Structural basis of cyclin-dependent kinase activation by phosphorylation
Russo, A. A., Jeffrey, P. D., & Pavletich, N. P. (1996) · Nature Structural & Molecular Biology · doi:10.1038/nsb0896-696 · Cited by 598
Luttrell, L. M., Hawes, B. E., van Biesen, T., Luttrell, D. K., Lansing, T. J., & Lefkowitz, R. J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.32.19443 · Cited by 525
Research works printed but not linked: 4
- A E Ottenhoff-Kalff, G Rijksen, E A van Beurden, A Hennipman, A A Michels, G E Staal Cancer Res 52, 4773–4778 (1992).
- Biscardi J. S. Tice D. A. & Parsons S. J. (1999) Adv. Cancer Res. 76 in press.
- 10.1128/mcb.11.9.4698-4709.1991 · doi:10.1128/mcb.11.9.4698-4709.1991
- E Vigna, L Naldini, L Tamagnone, P Longati, A Bardelli, F Maina, C Ponzetto, P M Comoglio Cell Mol Biol 40, 597–604 (1994).
Cited by
Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways
Wee, P., & Wang, Z. (2017) · Cancers · doi:10.3390/cancers9050052 · Cited by 2,027
Epidermal growth factor receptor: Mechanisms of activation and signalling
Jorissen, R. (2003) · Experimental Cell Research · doi:10.1016/s0014-4827(02)00098-8 · Cited by 1,565
The ErbB/HER family of protein-tyrosine kinases and cancer
Roskoski, R. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2013.11.002 · Cited by 1,353
Yun, C.-H., Boggon, T. J., Li, Y., Woo, M. S., Greulich, H., Meyerson, M., & Eck, M. J. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.12.017 · Cited by 1,192
A comprehensive pathway map of epidermal growth factor receptor signaling
Oda, K., Matsuoka, Y., Funahashi, A., & Kitano, H. (2005) · Molecular Systems Biology · doi:10.1038/msb4100014 · Cited by 1,158
A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib)
Wood, E. R., Truesdale, A. T., McDonald, O. B., Yuan, D., Hassell, A., Dickerson, S. H., Ellis, B., Pennisi, C., Horne, E., Lackey, K., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1168 · Cited by 1,122
Yeatman, T. J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1366 · Cited by 1,113
“In support of this, when EGFR and c-SRC are co-transfected into fibroblasts, their combined action results in increased proliferation, invasiveness and tumorigenesi”
BackgroundRoskoski, R. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2015.10.021 · Cited by 886
Role of Src expression and activation in human cancer
Irby, R. B., & Yeatman, T. J. (2000) · Oncogene · doi:10.1038/sj.onc.1203912 · Cited by 857
Garcia, R., Bowman, T. L., Niu, G., Yu, H., Minton, S., Muro-Cacho, C. A., Cox, C. E., Falcone, R., Fairclough, R., Parsons, S., et al. (2001) · Oncogene · doi:10.1038/sj.onc.1204349 · Cited by 756
Self-citationDerailed endocytosis: an emerging feature of cancer
Mosesson, Y., Mills, G. B., & Yarden, Y. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2521 · Cited by 718
Src in cancer: deregulation and consequences for cell behaviour
Frame, M. C. (2002) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(02)00040-9 · Cited by 683
Prenzel, N., Fischer, O. M., Streit, S., Hart, S., & Ullrich, A. (2001) · Endocrine-related cancer · doi:10.1677/erc.0.0080011 · Cited by 673
Kefas, B., Godlewski, J., Comeau, L., Li, Y., Abounader, R., Hawkinson, M., Lee, J., Fine, H., Chiocca, E. A., Lawler, S., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6639 · Cited by 647
ErbB Receptors: Directing Key Signaling Networks Throughout Life
Holbro, T., & Hynes, N. E. (2004) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.44.101802.121440 · Cited by 640
Zhang, S., Huang, W.-C., Li, P., Guo, H., Poh, S.-B., Brady, S. W., Xiong, Y., Tseng, L.-M., Li, S.-H., Ding, Z., et al. (2011) · Nature Medicine · doi:10.1038/nm.2309 · Cited by 515
Endocytosis of Receptor Tyrosine Kinases
Goh, L. K., & Sorkin, A. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a017459 · Cited by 461
Mitogenic signaling pathways induced by G protein‐coupled receptors
Rozengurt, E. (2007) · Journal of Cellular Physiology · doi:10.1002/jcp.21246 · Cited by 460
The interplay between Src family kinases and receptor tyrosine kinases
Bromann, P. A., Korkaya, H., & Courtneidge, S. A. (2004) · Oncogene · doi:10.1038/sj.onc.1208079 · Cited by 454
Wang, Z. (2017) · Methods in Molecular Biology · doi:10.1007/978-1-4939-7219-7_1 · Cited by 430
Plattner, R., Kadlec, L., DeMali, K. A., Kazlauskas, A., & Pendergast, A. M. (1999) · Genes & Development · doi:10.1101/gad.13.18.2400 · Cited by 427
Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis
Silva, C. M. (2004) · Oncogene · doi:10.1038/sj.onc.1208159 · Cited by 403
Integrin and Growth Factor Receptor Crosstalk
Eliceiri, B. P. (2001) · Circulation Research · doi:10.1161/hh2401.101084 · Cited by 395
Src Family Tyrosine Kinases and Growth Factor Signaling
Abram, C. L., & Courtneidge, S. A. (2000) · Experimental Cell Research · doi:10.1006/excr.1999.4732 · Cited by 391
Phospholipase D: Enzymology, Functionality, and Chemical Modulation
Selvy, P. E., Lavieri, R. R., Lindsley, C. W., & Brown, H. A. (2011) · Chemical Reviews · doi:10.1021/cr200296t · Cited by 389
Yan, F., Cao, H., Cover, T. L., Washington, M. K., Shi, Y., Liu, L., Chaturvedi, R., Peek, R. M., Wilson, K. T., & Polk, D. B. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44031 · Cited by 375
Positional Control of Cell Fate Through Joint Integrin/Receptor Protein Kinase Signaling
Giancotti, F. G., & Tarone, G. (2003) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.19.031103.133334 · Cited by 374
p27 Phosphorylation by Src Regulates Inhibition of Cyclin E-Cdk2
Chu, I., Sun, J., Arnaout, A., Kahn, H., Hanna, W., Narod, S., Sun, P., Tan, C.-K., Hengst, L., & Slingerland, J. (2007) · Cell · doi:10.1016/j.cell.2006.11.049 · Cited by 372
Haas, M., Askari, A., & Xie, Z. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m002951200 · Cited by 363
Song, L., Turkson, J., Karras, J. G., Jove, R., & Haura, E. B. (2003) · Oncogene · doi:10.1038/sj.onc.1206479 · Cited by 362
The Role of Src in Solid Tumors
Wheeler, D. L., Iida, M., & Dunn, E. F. (2009) · The Oncologist · doi:10.1634/theoncologist.2009-0009 · Cited by 346
“Given the clear rationale for targeting SFKs and EGFR many of the latest therapies that are effective in the treatment of NSCLC involve inhibition of these molecules [68–70] (Fig.”
BackgroundThe EGF receptor as central transducer of heterologous signalling systems
Zwick, E., Hackel, P. O., Prenzel, N., & Ullrich, A. (1999) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(99)01373-5 · Cited by 343
Biscardi, J. S., Ishizawar, R. C., Silva, C. M., & Parsons, S. J. (2000) · Breast Cancer Research · doi:10.1186/bcr55 · Cited by 323
Self-citationCatalytic Control in the EGF Receptor and Its Connection to General Kinase Regulatory Mechanisms
Jura, N., Zhang, X., Endres, N. F., Seeliger, M. A., Schindler, T., & Kuriyan, J. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.03.004 · Cited by 310
Structure and Clinical Relevance of the Epidermal Growth Factor Receptor in Human Cancer
Kumar, A., Petri, E. T., Halmos, B., & Boggon, T. J. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.1178 · Cited by 308
Shupnik, M. A. (2004) · Oncogene · doi:10.1038/sj.onc.1208076 · Cited by 301
A chemical and phosphoproteomic characterization of dasatinib action in lung cancer
Li, J., Rix, U., Fang, B., Bai, Y., Edwards, A., Colinge, J., Bennett, K. L., Gao, J., Song, L., Eschrich, S., et al. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.332 · Cited by 283
Hiscox, S., Morgan, L., Green, T. P., Barrow, D., Gee, J., & Nicholson, R. I. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-005-9120-9 · Cited by 274
Employment of the Epidermal Growth Factor Receptor in Growth Factor–Independent Signaling Pathways
Carpenter, G. (1999) · The Journal of Cell Biology · doi:10.1083/jcb.146.4.697 · Cited by 272
Lu, Y., Li, X., Liang, K., Luwor, R., Siddik, Z. H., Mills, G. B., Mendelsohn, J., & Fan, Z. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0589 · Cited by 170
Current status of SRC inhibitors in solid tumor malignancies
Puls, L. N., Eadens, M., & Messersmith, W. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0408 · Cited by 158
Wheeler, D. L., Iida, M., Kruser, T. J., Nechrebecki, M. M., Dunn, E. F., Armstrong, E. A., Huang, S., & Harari, P. M. (2009) · Cancer Biology & Therapy · doi:10.4161/cbt.8.8.7903 · Cited by 157
UBPY-mediated Epidermal Growth Factor Receptor (EGFR) De-ubiquitination Promotes EGFR Degradation
Alwan, H. A. J., & van Leeuwen, J. E. M. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m604711200 · Cited by 140
Rexer, B. N., Ham, A.-J. L., Rinehart, C., Hill, S., de Matos Granja-Ingram, N., González-Angulo, A. M., Mills, G. B., Dave, B., Chang, J. C., Liebler, D. C., et al. (2011) · Oncogene · doi:10.1038/onc.2011.130 · Cited by 139
Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab
Dunn, E. F., Iida, M., Myers, R. A., Campbell, D. A., Hintz, K. A., Armstrong, E. A., Li, C., & Wheeler, D. L. (2011) · Oncogene · doi:10.1038/onc.2010.430 · Cited by 133
“These membrane-associated non-RTKs are transducers of mitogenic signaling emanating from a number of RTKs, including EGFR, HER2, fibroblast growth factor receptor, platelet-derived growth factor, colonystimulating factor-1 receptor and hepatocyte growth receptor (Muthuswamy et al., 1994; Belsches et al., 1997; Mao et…”
BackgroundWang, X.-Q., Sun, P., & Paller, A. S. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m308818200 · Cited by 87
Arcaroli, J. J., Touban, B. M., Tan, A. C., Varella-Garcia, M., Powell, R. W., Eckhardt, S. G., Elvin, P., Gao, D., & Messersmith, W. A. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0066 · Cited by 64
Panupinthu, N., Yu, S., Zhang, D., Zhang, F., Gagea, M., Lu, Y., Grandis, J. R., Dunn, S. E., Lee, H. Y., & Mills, G. B. (2014) · Oncogene · doi:10.1038/onc.2013.259 · Cited by 49
Yuan, M., Xu, L.-F., Zhang, J., Kong, S.-Y., Wu, M., Lao, Y.-Z., Zhou, H., Zhang, L., & Xu, H. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00586 · Cited by 26
SRC at the Crossroads of KRAS Inhibitor Resistance: Mechanisms and Therapeutic Opportunities
Tian, H., Zhao, D., Zhou, Z., Kim, A., Huang, H., Lee, Y. J., Qu, Z., Kang, R., Zeh, H. J., Westover, K. D., et al. (2026) · Cancer Letters · doi:10.1016/j.canlet.2025.218194 · Cited by 7
Metadata
- Authors
- Tice, D. A., Biscardi, J. S., Nickles, A. L., & Parsons, S. J.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1999-02-16
- Volume
- 96
- Issue
- 4
- Pages
- 1415-1420
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2076718022
- Cited by
- 472
- References
- 33
- FWCI
- 7.21
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.